Exelixis Entering Critical Six-Month Period

Cabozantinib is also in 45 ongoing or planned clinical trials, including pivotal Phase 3 trials in metastatic renal cell cancer (mRCC) in METEOR and advanced hepatocellular cancer (CELESTIAL).04/02/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news